Compare KELYA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | AQST |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.2M | 529.4M |
| IPO Year | 1994 | 2007 |
| Metric | KELYA | AQST |
|---|---|---|
| Price | $13.76 | $3.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $20.00 | $9.33 |
| AVG Volume (30 Days) | 296.0K | ★ 2.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | ★ $67,430,000.00 |
| Revenue This Year | N/A | $14.58 |
| Revenue Next Year | $3.70 | $32.78 |
| P/E Ratio | $112.73 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $7.98 | $2.94 |
| 52 Week High | $17.75 | $6.74 |
| Indicator | KELYA | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 31.28 | 32.82 |
| Support Level | $8.79 | $2.94 |
| Resistance Level | $16.61 | $4.34 |
| Average True Range (ATR) | 0.79 | 0.22 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 8.70 | 6.08 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.